IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科
学科主题临床医学
Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study
Zhao, Shui-ping1; Peng, Dao-quan1; Yu, Bi-lian1; Huo, Yong2; CHILLAS Investigators
刊名AMERICAN HEART JOURNAL
2009-10-01
DOI10.1016/j.ahj.2009.07.030
158期:4页:509-U1
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]HIGH-DOSE ATORVASTATIN ; CONTROLLED TRIAL ; CHOLESTEROL ; DISEASE ; EVENTS ; SIMVASTATIN ; PRAVASTATIN ; PREVENTION
英文摘要

Background Current guidelines recommended intensive low-density lipoprotein cholesterol lowering with statins, aiming at the target of 70 mg/dL (1.81 mmol/L) of low-density lipoprotein cholesterol for those with very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid lowering therapy with statins on acute coronary syndrome (ACS) in Chinese population.

Methods An open-label multicenter study is planned to evaluate whether intensive treatment with statins for 2 to 5 years results in more reduction of cardiovascular events in patients with ACS compared to the standard statin therapy. A total of 1,600 patients will be randomly assigned to receive intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins) or standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins). Both groups will receive dietary counseling. Over the follow-up period, the primary outcome measure is the time to occurrence of cardiac death, nonfatal acute myocardial infarction, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting, documented unstable angina or severe heart failure requiring emergency hospitalization, and stroke. The planned duration for enrollment is between December 2006 and December 2009.

Conclusions The CHILLAS study will be the first multicenter study in a Chinese population using a patient-level analysis to compare the effects and safety of intensive statin therapy with that of standard-dose statin therapy, which may provide new evidence and therapeutic standards for the treatment of ACS. (Am Heart J 2009; 158:509-12.)

语种英语
WOS记录号WOS:000270706100003
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60981
专题北京大学第一临床医学院_心血管内科
作者单位1.Cent S Univ, Xiangya Hosp 2, Dept Cardiol, Changsha 410011, Hunan, Peoples R China
2.Peking Univ, Hosp 1, Dept Cardiol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Zhao, Shui-ping,Peng, Dao-quan,Yu, Bi-lian,et al. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study[J]. AMERICAN HEART JOURNAL,2009,158(4):509-U1.
APA Zhao, Shui-ping,Peng, Dao-quan,Yu, Bi-lian,Huo, Yong,&CHILLAS Investigators.(2009).Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study.AMERICAN HEART JOURNAL,158(4),509-U1.
MLA Zhao, Shui-ping,et al."Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study".AMERICAN HEART JOURNAL 158.4(2009):509-U1.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Shui-ping]的文章
[Peng, Dao-quan]的文章
[Yu, Bi-lian]的文章
百度学术
百度学术中相似的文章
[Zhao, Shui-ping]的文章
[Peng, Dao-quan]的文章
[Yu, Bi-lian]的文章
必应学术
必应学术中相似的文章
[Zhao, Shui-ping]的文章
[Peng, Dao-quan]的文章
[Yu, Bi-lian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。